GCM
GILD icon

Glaxis Capital Management’s Gilead Sciences GILD Stock Holding History

Glaxis Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,000
Closed -$414K – 29
2014
Q2 		$414K Buy
+5,000
New +$389K 0.9% 34
2013
Q4 		– Sell
-13,200
Closed -$830K – 42
2013
Q3 		$830K Sell
13,200
-18,750
-59% -$1.12M 1.67% 24
2013
Q2 		$1.64M Buy
+31,950
New +$1.67M 3.86% 9

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glaxis Capital Management's GILD Position: Q3 2014 in Review

Glaxis Capital Management sold out of Gilead Sciences (GILD) in Q3 2014, closing a stake of 5,000 shares — an estimated $414K sold.

Glaxis Capital Management first reported a position in GILD in Q2 2013 and held it in 3 quarters. The position peaked at $1.64M in Q2 2013. 1,326 funds tracked by Wall St. Rank hold GILD as of Q3 2014.

  • Glaxis Capital Management reported no remaining Gilead Sciences position as of Q3 2014 after selling out during the quarter.
  • Glaxis Capital Management sold 5,000 Gilead Sciences shares in Q3 2014, an estimated $414K.
  • Glaxis Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 3 quarters.
  • Glaxis Capital Management's Gilead Sciences position peaked at $1.64M in Q2 2013.
  • 1,326 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2014.

Based on Glaxis Capital Management's 13F filing for Q3 2014, filed 24 Oct 2014.